100 existing species – most common types are B. microti and B. divergens
Risk Factors for severe disease
Splenectomy
Immunosuppression
Clinical Presentation
Most cases of human Babesia infection are asymptomatic
Symptomatic patients experience fever, headache, nausea, sweats and rigors
Symptoms occur 1 to 6 weeks following tick bite
The resemblance to a fulminating malaria-like infection may complicate initial diagnosis
Severe cases can result in hemolytic anemia and thrombocytopenia due to fragmentation of red blood cells by the parasite, resulting in capillary blockage in the spleen, liver, kidneys and central nervous system
Immunocompromised patients may experience persistent or relapsing disease
Diagnosis
Laboratory testing
Giemsa-stained blood films (in patients from endemic areas)
Diagnostic if parasites noted
Relatively insensitive due to low level parasitemia in most patients
IFA testing
High sensitivity and specificity in Babesia detection
Test of choice for laboratory diagnosis
Rises 2-4 weeks after infection and wanes at 6-12 months
Use along with B. microti antibody in patients with history of travel or residence in endemic area
Thick smears made from hemolyzed blood are the most useful for screening purposes in cases with low-level parasitemia; thin smears are used for parasite classification
Although microscopic examination of thin smear blood samples is the accepted method for Babesia diagnosis, low parasitemia levels may hamper detection
Time sensitive
Babesia microti Antibodies, IgG & IgM by IFA 0093048
Method: Indirect Fluorescent Antibody
Detect B. microti-specific IgG and IgM antibodies in patient’s serum samples where there is a clinical suspicion of B. microti infection (patients with history of travel or residence in endemic area)
Additional Tests Available
Click on number for test-specific information in the ARUP Laboratory Test Directory
Belongia EA.Epidemiology and impact of coinfections acquired from Ixodes ticks.Vector Borne Zoonotic Dis. 2002;2(4):265-273. (Link to PubMed)
Cable RG, Leiby DA.Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases.Curr Opin Hematol. 2003;10(6):405-411. (Link to PubMed)
Krause PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, Telford SR III, Sikand V, Ryan R, Persing D, Radolf JD, Spielman A.Increasing health burden of human babesiosis in endemic sites.Am J Trop Med Hyg. 2003;68(4):431-436. (Link to PubMed)
Krause PJ.Babesiosis diagnosis and treatment.Vector Borne Zoonotic Dis. 2003;3(1):45-51. (Link to PubMed)
Lantos PM, Krause PJ.Babesiosis: similar to malaria but different.Pediatr Ann. 2002;31(3):192-197. (Link to PubMed)
Leiby DA.Emerging infectious agents.Dev Biol (Basel). 2005;120:11-15. (Link to PubMed)
Mylonakis E.When to suspect and how to monitor babesiosis.Am Fam Physician. 2001;63(10):1969-1974. (Link to PubMed)
Reviewed by
Carney, Heather, M.D. Assistant Medical Director, Transfusion Services at ARUP Laboratories; Pathology, University of Utah
Litwin, Christine, M.D. Medical Director, Immunology at ARUP Laboratories; Professor, Clinical Pathology, University of Utah
Petti, Cathy A., M.D. Medical Director, Infectious Diseases at ARUP Laboratories; Assistant Professor, Pathology and Medicine, University of Utah
Comprehensive Review: July 2008
Last Update: July 2008